0000899243-19-029172.txt : 20191213 0000899243-19-029172.hdr.sgml : 20191213 20191213174642 ACCESSION NUMBER: 0000899243-19-029172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191211 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pizzo Philip A. CENTRAL INDEX KEY: 0001574286 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 191285454 MAIL ADDRESS: STREET 1: ONE COMMERCE STREET STREET 2: SUITE 2550 CITY: MEMPHIS STATE: TN ZIP: 38103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-11 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001574286 Pizzo Philip A. C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2019-12-11 4 M 0 15000 18.85 A 15000 D Common Stock 2019-12-11 4 M 0 15000 28.45 A 30000 D Common Stock 2019-12-11 4 S 0 27868 76.5225 D 2132 D Common Stock 2019-12-11 4 S 0 2132 77.2507 D 0 D Stock Option (Right to Buy) 18.85 2019-12-11 4 M 0 15000 0.00 D 2026-06-15 Common Stock 15000 0 D Stock Option (Right to Buy) 28.45 2019-12-11 4 M 0 15000 0.00 D 2027-06-19 Common Stock 15000 0 D Represents the weighted average sale price of the shares sold from $76.12 to $77.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2. Represents the weighted average sale price of the shares sold from $77.12 to $77.38 per share. The shares underlying this option vested and became exercisable in 12 equal monthly installments, with the first installment on July 16, 2016. The shares underlying this option vested and became exercisable in 12 equal monthly installments, with the first installment on July 20, 2017. /s/Lesley Ann Calhoun, as Attorney-in-Fact 2019-12-13